Drug Profile
PF 06688992
Alternative Names: anti GD3 ADC PF-06688992; GD3 ADC; GD3 ADC PF-06688992; PF-06688992Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Memorial Sloan-Kettering Cancer Center; Pfizer
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 10 Jan 2020 Pfizer and Memorial Sloan Kettering Cancer completes a phase I trial in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03159117)
- 17 May 2017 Phase-I clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03159117)